Roquefort Therapeutics PLC - London-based biotechnology company - Says it has opted against a fundraise following "unusual share price movements". The company had engaged advisers to commence "market soundings" in relation to a potential placing, but says that "incorrect bulletin board comments regarding a speculative placing price," which in turn impacted its share price, turned it against the idea. Shares in Roquefort dropped 36% on Thursday from 6.89 pence each to 4.41 pence, having hovered around the 7p mark for the whole of March.
Current stock price: 4.18 pence per share, down 7.0% in London on Friday
12-month change: down 39%
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Roquefort Thera (ROQ)